Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.44USD
15 Dec 2017
Change (% chg)

$-0.08 (-2.27%)
Prev Close
$3.52
Open
$3.49
Day's High
$3.50
Day's Low
$3.40
Volume
95,335
Avg. Vol
33,954
52-wk High
$5.11
52-wk Low
$1.90

Select another date:

Tue, Dec 12 2017

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL

BRIEF-Fortress Biotech forms subsidiary Tamid Bio to develop novel aav gene therapies in Orphan Diseases

* FORTRESS BIOTECH FORMS SUBSIDIARY TAMID BIO TO DEVELOP NOVEL AAV GENE THERAPIES IN ORPHAN DISEASES WITH UNMET MEDICAL NEEDS Source text for Eikon: Further company coverage:

BRIEF-Mustang Bio names new vice president of finance and corporate controller

* Mustang Bio announces appointment of Brian Achenbach as vice president of finance and corporate controller Source text for Eikon: Further company coverage:

BRIEF-Fortress Biotech posts Q3 loss per share $0.67

* Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights

BRIEF-Fortress Biotech announces pricing of series a preferred stock offering

* Fortress Biotech Inc announces pricing of series a preferred stock offering

BRIEF-Fortress Biotech proposes public offering of Series A preferred stock

* Fortress Biotech announces proposed public offering of Series A preferred stock Source text for Eikon: Further company coverage:

BRIEF-Mustang Bio enters lease agreement for production of Car T therapies

* Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​

BRIEF-Fortress Biotech reports Q2 loss per share $0.43

* Fortress Biotech reports second quarter 2017 financial results and recent corporate highlights

BRIEF-Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101

* Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101 Source text for Eikon: Further company coverage:

BRIEF-Fortress Biotech says Lucy Lu, MD, appointed CEO of unit Avenue Therapeutics

* Fortress biotech announces appointment of lucy lu, md, as president and chief executive officer of subsidiary avenue therapeutics

Select another date: